Metformin is the best first-line medicine for most people newly diagnosed with type 2 diabetes. It’s effective, affordable, well-studied over decades, and carries a low risk of dangerous blood sugar drops. But “best” depends on your full health picture. If you have heart disease, heart failure, or kidney problems, newer drug classes may offer protective benefits that metformin alone does not.
Why Metformin Comes First
Metformin works by reducing the amount of sugar your liver releases into your bloodstream and helping your cells respond better to insulin. For someone newly diagnosed and without complications, major guidelines recommend starting metformin as a single agent, then adding other medications over time if blood sugar stays too high. It’s available as a cheap generic, taken once or twice daily, and it doesn’t cause weight gain.
The most common side effect is diarrhea, especially in the first few weeks. Starting at a low dose and increasing gradually helps most people tolerate it. Extended-release versions also cause less stomach upset. Metformin does have one firm limit: kidney function. If your kidneys are filtering below a certain threshold (an eGFR below 30), metformin is off the table. Between 30 and 45, your doctor will weigh whether the benefits still outweigh the risks and may reduce the dose.
GLP-1 Receptor Agonists: Strong on Blood Sugar and Weight
This class includes medications like semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro). They mimic a gut hormone that tells your pancreas to release insulin when blood sugar rises, slows digestion, and reduces appetite. The result is both significant blood sugar reduction and meaningful weight loss, which makes them especially useful since most people with type 2 diabetes also struggle with excess weight.
GLP-1 receptor agonists lower A1c by an average of 0.8% to 1.6%, which is comparable to or better than metformin for many patients. Tirzepatide, which targets two gut hormones instead of one, produces even more weight loss than semaglutide. In a large comparison study, patients on tirzepatide were more than three times as likely to lose 15% or more of their body weight. At 12 months, tirzepatide users had lost roughly 7 percentage points more body weight than those on semaglutide.
Beyond blood sugar and weight, these drugs protect the cardiovascular system. A large meta-analysis in Circulation found that GLP-1 receptor agonists reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 21%. They also cut hospitalizations for heart failure and slowed kidney disease progression. These benefits held up whether or not patients were also taking an SGLT2 inhibitor.
Most GLP-1 medications are given as a weekly injection using a small pen device, though an oral tablet form of semaglutide (Rybelsus) exists. The main downsides are nausea, which usually fades over the first few weeks as your dose ramps up, and cost. These are brand-name drugs with no generic versions yet, and a month’s supply can run over $1,000 without insurance coverage.
SGLT2 Inhibitors: Heart and Kidney Protection
SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) work through a completely different mechanism. They block your kidneys from reabsorbing sugar back into the blood, so you excrete excess glucose in your urine. This lowers blood sugar by about 0.5% to 1.0% A1c on average, which is moderate compared to GLP-1 drugs, but the real value is what they do for your heart and kidneys.
Clinical guidelines from cardiology, endocrinology, and nephrology organizations all recommend SGLT2 inhibitors for people with type 2 diabetes who have heart failure or chronic kidney disease. The cardiovascular and kidney benefits appear to be independent of blood sugar control, meaning these drugs protect organs through mechanisms beyond just lowering glucose. When combined with a GLP-1 receptor agonist, the protective effects on heart and kidney outcomes are likely additive.
Side effects reflect how the drug works. Because sugar is leaving through your urine, you’ll urinate more frequently, and the sugar-rich environment increases the risk of genital yeast infections and urinary tract infections. Dizziness can occur from fluid loss. Rare but serious risks include a type of diabetic ketoacidosis (dangerously acidic blood) that can happen even when blood sugar isn’t particularly high, and an extremely rare genital infection called Fournier gangrene. Staying hydrated and maintaining good hygiene reduces most of the common risks.
Sulfonylureas: Effective but Riskier
Sulfonylureas (glipizide, glimepiride, glyburide) are older, inexpensive medications that stimulate your pancreas to produce more insulin regardless of whether your blood sugar is high or low. That “always on” mechanism is exactly what makes them risky. About 20% of people on sulfonylureas experience hypoglycemia (blood sugar dropping too low), and the rate increases the longer you take them. Symptoms range from shakiness and sweating to confusion and, in severe cases, loss of consciousness.
They also tend to cause weight gain. For these reasons, sulfonylureas have been moved further down the treatment ladder in most current guidelines. They still have a role when cost is a major barrier, since generics cost only a few dollars per month, but newer options are preferred when accessible.
DPP-4 Inhibitors: Gentle but Limited
DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) work by boosting the same gut hormone system that GLP-1 drugs target, but much more gently. They produce modest A1c reductions, don’t cause weight gain, and carry a low risk of hypoglycemia when used alone. They’re taken as a daily pill, which some people prefer over injections.
The trade-off is that DPP-4 inhibitors don’t offer the cardiovascular or kidney protection seen with GLP-1 agonists and SGLT2 inhibitors, and they produce less blood sugar reduction. They fit best as an add-on for someone who needs a little extra glucose lowering without added side effects. One caution: adding a DPP-4 inhibitor to a sulfonylurea increases hypoglycemia risk because both drugs push insulin secretion. In studies, the combination raised the absolute rate of low blood sugar episodes to about 12%, compared to 7% on a sulfonylurea alone.
How Your Health Profile Shapes the Choice
No single drug is best for everyone. The decision depends on which problems matter most in your case.
- Newly diagnosed, no complications: Metformin is the starting point. It’s proven, affordable, and effective.
- Heart disease or high cardiovascular risk: A GLP-1 receptor agonist added to metformin provides the strongest evidence for preventing heart attacks and strokes.
- Heart failure or chronic kidney disease: An SGLT2 inhibitor is specifically recommended, often regardless of your blood sugar level.
- Significant excess weight: GLP-1 receptor agonists or tirzepatide offer the most weight loss alongside blood sugar control.
- Cost is the primary concern: Metformin and sulfonylureas are available as inexpensive generics. Newer brand-name drugs may be inaccessible without insurance.
Many people with type 2 diabetes end up on two or three medications from different classes, each addressing a different aspect of the disease. The combination of metformin plus a GLP-1 receptor agonist plus an SGLT2 inhibitor, for instance, covers blood sugar reduction, weight management, and organ protection simultaneously. Treatment typically starts simple and builds over time based on how your body responds and how the disease progresses.
The Cost Factor
The practical reality is that the “best” medication is sometimes the one you can actually afford and take consistently. Metformin costs a few dollars a month. Sulfonylureas and DPP-4 inhibitors are also relatively affordable, especially as generics. GLP-1 receptor agonists and SGLT2 inhibitors are significantly more expensive, often requiring brand-name pricing. A month’s supply of injectable semaglutide or tirzepatide can exceed $1,000 at list price in the United States, though manufacturer savings programs and insurance formularies can reduce out-of-pocket costs substantially. An oral form of semaglutide exists as a daily tablet for people who prefer not to inject, though it remains a brand-name product at brand-name pricing.
If newer medications are financially out of reach, metformin combined with lifestyle changes (even modest weight loss of 5% to 7% improves insulin sensitivity meaningfully) remains a strong foundation. The best diabetes medication is ultimately one that controls your blood sugar, fits your health risks, and stays in your routine month after month.